Expanded access to burosumab for x-linked hypophosphatemia
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This program provides access to a medication called burosumab (Crysvita) for people with a rare genetic condition called X-linked hypophosphatemia (XLH), which causes weak bones and low phosphate levels. It is designed for those who cannot get the drug through normal channels or other clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a condition called X-linked hypophosphatemia (XLH), a rare genetic disorder that causes low phosphate levels in the blood.
- You are not able to get burosumab (also known as Crysvita) through a regular prescription or other clinical trial.
- You have a healthcare provider who is willing to request this medication for you through the expanded access program.
- You are not currently enrolled in another investigational treatment for the same condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called KK8123 for adults with X-linked hypophosphatemia (XLH), a rare condition that causes low phosphate levels and can lead to bone problems. The goal is to see if it helps improve phosphate levels in the body.
This registry collects information about people diagnosed with X-linked hypophosphatemia (XLH). It helps researchers better understand the condition and may support future studies by tracking patients over time.
This study uses a special MRI scan to look at phosphorus levels in the muscles of people with phosphate diabetes (a condition where the body loses too much phosphate through the kidneys). It aims to better understand how this condition affects muscles and may help guide future treatments.
This study looks at how young people with X-linked hypophosphataemia (XLH) respond to different doses of burosumab. The goal is to find the best dose to manage the condition.
This study tests whether burosumab and vitamin D affect bone cells before and around the time of craniosynostosis surgery in children. It may help researchers understand treatment options for rare calcium and phosphate bone disorders that can affect skull growth.
This early study looks at how the body’s handling of phosphate may affect aging and bone health. It is meant for people with certain rare genetic conditions that change phosphate levels, to better understand their biology and responses to study tests.
Hear when a new X-linked Hypophosphatemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.